Bloomage Biotech(SH:688363) Xin Hua Cai Jing·2025-11-04 11:31Core Viewpoint - The orderly exit of institutional shareholders and the continuous increase in holdings by the controlling shareholder create a positive balance, optimizing the company's equity structure and enhancing market liquidity and capital stability, which is favorable for long-term investors [2] Group 1: Shareholder Actions - The shareholder Guoshou Chengda plans to reduce its stake in Huaxi Biotechnology by up to 2% of the total share capital between November 24, 2025, and February 20, 2026, as part of a normal exit within the fund's investment cycle [1] - After the reduction, Guoshou Chengda's shareholding will fall below 5%, eliminating its status as a related party, which may allow insurance and asset management funds to re-enter Huaxi Biotechnology for investment [1] - The controlling shareholder, Huaxi Xinyu Investment Co., completed an increase in holdings by acquiring approximately 4.519 million shares for about 257 million yuan, raising its stake to 60.11% [1] Group 2: Business Strategy and Market Position - Huaxi Biotechnology focuses on synthetic biology manufacturing, establishing an integrated business layout in the field of aging intervention, providing comprehensive solutions across pharmaceuticals, medical aesthetics, nutritional science, and dermatology [2] - The company is one of the few globally that covers almost all key materials in the ECM (extracellular matrix) field, with a core research direction centered on the overall synergy of ECM key materials [2] - Huaxi Biotechnology's growth stems from its ability to integrate various scientific dimensions, including ECM stability and regeneration, cellular energy maintenance, and precise intercellular communication [3] Group 3: Innovation and Development - The company exemplifies the transition of Chinese manufacturing enterprises towards foundational research and brand transformation, leveraging technological innovation to drive industry evolution [4] - Huaxi Biotechnology has become a global leader in hyaluronic acid production, transitioning from animal extraction to microbial fermentation and cell factory production, significantly reducing costs while improving quality and stability [4] - The profits generated are reinvested into foundational and applied research, particularly in aging and regenerative medicine, opening doors to cellular biology and glycoscience [4]